Sanofi has confirmed the deal to buy U.S. peer Bioverativ for $11.6 billion. The French healthcare company intends to boost its earnings and strengthen its presence in the field of treatments for rare diseases. Sanofi has agreed to buy all of the outstanding shares of Bioverativ for $105 per share in cash, marking a premium of 64 percent to Bioverativ's closing price.

Sanofi expects the acquisition to be immediately accretive to its business earnings per share in the 2018 full financial year and up to 5 percent accretive for the following year. Sanofi is also projected to achieve a return on its invested capital (ROIC) in excess of the cost of capital within three years.

With Bioverativ, a leader in the growing hemophilia market, Sanofi plans to enhance its presence in specialty care and leadership in rare diseases, in line with its 2020 Roadmap, and to create a platform for growth in other rare blood disorders.